Last $3.81 USD
Change Today +0.13 / 3.53%
Volume 68.3K
As of 2:36 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

vascular biogenics ltd (VBLT) Snapshot

Open
$3.66
Previous Close
$3.68
Day High
$3.91
Day Low
$3.63
52 Week High
01/27/15 - $17.02
52 Week Low
03/4/15 - $3.63
Market Cap
75.5M
Average Volume 10 Days
214.3K
EPS TTM
--
Shares Outstanding
19.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VASCULAR BIOGENICS LTD (VBLT)

vascular biogenics ltd (VBLT) Related Bloomberg News

View More Bloomberg News

vascular biogenics ltd (VBLT) Related Businessweek News

No Related Businessweek News Found

vascular biogenics ltd (VBLT) Details

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead product candidates include VB-111, a gene-based biologic, which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer, as well as VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel.

32 Employees
Last Reported Date: 11/13/14
Founded in 2000

vascular biogenics ltd (VBLT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

vascular biogenics ltd (VBLT) Key Developments

VBL Therapeutics Announces Removal of FDA Partial Clinical Hold on VB-111

VBL Therapeutics announced that the U.S. Food and Drug Administration (FDA) has determined that VBL may proceed with its pivotal Phase 3 trial in patients with recurrent glioblastoma (rGBM) and removed the clinical hold on the trial, allowing the trial to proceed under a previously agreed upon special protocol assessment (SPA). In July 2014, the Phase 3 study of VB-111 in rGBM was placed on clinical hold, pending the submission of additional properties regarding the VB-111 potency assay developed by VBL. Also in July 2014, pursuant to VBL's request for an SPA, the FDA issued a concurrence with the design and planned analyses of this pivotal trial for a randomized, controlled, double-arm, open-label study of VB-111 with a primary endpoint of increased overall survival. Interim data is expected in the second half of 2016. VBL recently reported positive data for VB-111 in rGBM and in thyroid cancer and is currently evaluating VB-111 in a clinical trial for ovarian cancer. VBL has also received fast track designation for VB-111 in the United States for prolongation of survival in patients with recurrent rGBM and orphan drug designation in both the United States and Europe. VBL also reported that it will discontinue development of a separate pipeline candidate VB-201 in ulcerative colitis and psoriasis following results of Phase 2 studies in these indications.

VBL Therapeutics Announces Topline Results from Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis

VBL Therapeutics announced that its Phase 2 studies evaluating lead Lecinoxoid compound VB-201 in patients with psoriasis and ulcerative colitis did not meet their primary endpoints. The company does not plan to continue development of VB-201 in these indications. In a simultaneous release, VBL also announced that the U.S. Food and Drug Administration (FDA) determined that VBL may proceed with a pivotal Phase 3 trial in rGBM and removed the clinical hold previously imposed on the study. VBL plans to initiate this trial in mid-2015 under a special protocol assessment with the FDA. This Phase 2 randomized, double-blind, placebo-controlled study was designed to evaluate the safety and efficacy of VB-201 dosed at 80 mg or 160 mg daily for 24 weeks. The study evaluated 194 patients with moderate to severe plaque psoriasis. The primary efficacy endpoint of the study was PASI 50, or the proportion of patients who achieve at least 50% improvement from baseline PASI score, at weeks 16 and 24. No effect of VB-201 compared to placebo was observed on the primary or secondary endpoints at either dose level tested. The PASI 50 for VB-201 patients was 26.4% at 16 weeks and 34% at 24 weeks, with no significant difference between the 80 mg and 160 mg dose cohorts. The placebo PASI 50 at week 16 was 38%. This Phase 2 randomized, double-blind, placebo-controlled study was designed to evaluate the safety and efficacy of VB-201 dosed at 160 mg daily for 24 weeks. The study evaluated 112 patients with mild to moderate ulcerative colitis. The primary endpoint of the study was disease remission at weeks 12 and 24.

VBLTherapeutics to Present Preclinical Data at Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease

VBL Therapeutics announced that Eyal Breitbart, Ph.D., Vice President of Research and Operations of VBL, will present preclinical results evaluating the company's lead Lecinoxoid candidate, VB-201, for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis, in an oral presentation at the Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD), taking place on March 22 - 27, 2015 in Whistler, British Columbia, Canada. The reported data will include preclinical results in mice with NASH and liver fibrosis, and will assess key measures of efficacy related to inflammation and fibrosis. With a novel mechanism of action designed to mimic naturally occurring oxidized phospholipids with anti-inflammatory properties, VB-201 has the potential to address a range of chronic, immune-inflammatory and inflammatory-derived diseases. VBL recently completed two Phase 2 studies evaluating the efficacy of lead Lecinoxoid compound, VB-201, for the treatment of psoriasis and ulcerative colitis. Top line results from both studies are expected in the first quarter of 2015. Fibrosis is a major pathological feature of many chronic autoimmune diseases and Toll-like receptors (TLRs) have been implicated as being a part of the underlying pathogenesis. Driven by the mechanism of action of VB-201, which inhibits the TLR2 and CD14/TLR4 complexes as well as monocyte migration, VBL explored VB-201 in a liver fibrosis model as proof of concept for additional target indications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VBLT:US $3.81 USD +0.13

VBLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VBLT.
View Industry Companies
 

Industry Analysis

VBLT

Industry Average

Valuation VBLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VASCULAR BIOGENICS LTD, please visit www.vblrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.